Skip to main content

Table 1 Clinical and demographic features of the study subjects, as well as pharmacological treatments in patients with systemic lupus erythematosus

From: A2A adenosine receptor upregulation correlates with disease activity in patients with systemic lupus erythematosus

  Patients with SLE (n = 80), n (%)
Clinical parameters
 Female/male 71/9
 Age, years, mean ± SD 44 ± 11.9
 Disease duration, monthsa 139 ± 100
 SLEDAI-2 K score, mean ± SD 4 ± 4.3
 SDI, mean ± SD 0.8 ± 1.2
Disease activity patterns
 CQD 46 (57.5 %)
 CAD 18 (22.5 %)
 MDA 14 (17.5 %)
 RRD 2 (2.5 %)
Serological parameters
 aPL (aCL, β2-GPI, and/or LA) 39 (48.75 %)
 ENA 48 (60 %)
 Hypocomplementemia 53 (62.2 %)
 Anti-dsDNA antibody, ongoing/previous 41 (51.2 %)/17 (21.1 %)
Treatments
 Corticosteroids, 2.5 up to 12.5 mg/day 67 (83.7 %)
 Hydroxychloroquine, 200 mg/day 48 (60 %)
Ongoing immunosuppressant therapy 25 (31.2 %)
 Mycophenolate mofetil 11 (13.7 %)
 Cyclosporine A 4 (5 %)
 Azathioprine 5 (6.2 %)
 Methotrexate, 10–15 mg/week 3 (3.7 %)
 Thalidomide 1 (1.2 %)
 IVIg 1 (1.2 %)
 PEX 1 (1.2 %)
Anticoagulants 11 (13.7)
Antiaggregant 33 (41.25)
  1. Abbreviations: SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index 2000, SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, CQD clinical quiescent disease, MDA minimal disease activity, CAD chronic active disease, RRD relapsing-remitting disease, aPL antiphospholipid antibodies, aCL anticardiolipin antibodies, LA lupus anticoagulant, β 2 -GPI β2-glycoprotein I antibodies, ENA extractable nuclear antigen antibodies, PEX plasma exchange, IVIg intravenous immunoglobulin, anti-dsDNA anti-double-stranded DNA
  2. aDisease duration at the time of sample collection